FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020618126> ?p ?o ?g. }

• W2020618126 endingPage "1225" @default.
• W2020618126 startingPage "1219" @default.
• W2020618126 abstract "Purpose To assess the predictors of hypersensitivity reaction to chemoembolization procedures with cisplatin and Lipiodol suspension for the treatment of hepatocellular carcinoma (HCC). Materials and Methods Between February 2005 and December 2008, 434 patients with HCC were treated with chemoembolization with a cisplatin and Lipiodol suspension. This retrospective cohort study analyzed the incidence of hypersensitivity reactions as an adverse effect and their predictors by multivariate logistic regression analyses. Results In total, 847 chemoembolization procedures were carried out in 434 patients. The median number of procedures per patient was 2 (range, 1–12). Mean dose of cisplatin per chemoembolization session was 27 mg (range, 15.0–80.0 mg), and the median total dose of cisplatin per patient was 55 mg (range, 5.0–560.0 mg). Hypersensitivity reactions occurred in 14 patients (1.7%). The median number of chemoembolization procedures in these patients was 7 (range, 3–10). Mean dose of cisplatin per session was 22 mg (range, 9.2–35.7 mg), and the median total dose of cisplatin was 134 mg (range, 37–286 mg). On multivariate analysis, the only parameter that showed an independent association with hypersensitivity reactions was the performance of 3 or more than three chemoembolization procedures. Conclusions Performance of more than three chemoembolization procedures with a cisplatin and Lipiodol suspension was found to be independently associated with hypersensitivity reactions. Patients undergoing repeated chemoembolization procedures with cisplatin and Lipiodol suspension may experience hypersensitivity reactions as an adverse effect. To assess the predictors of hypersensitivity reaction to chemoembolization procedures with cisplatin and Lipiodol suspension for the treatment of hepatocellular carcinoma (HCC). Between February 2005 and December 2008, 434 patients with HCC were treated with chemoembolization with a cisplatin and Lipiodol suspension. This retrospective cohort study analyzed the incidence of hypersensitivity reactions as an adverse effect and their predictors by multivariate logistic regression analyses. In total, 847 chemoembolization procedures were carried out in 434 patients. The median number of procedures per patient was 2 (range, 1–12). Mean dose of cisplatin per chemoembolization session was 27 mg (range, 15.0–80.0 mg), and the median total dose of cisplatin per patient was 55 mg (range, 5.0–560.0 mg). Hypersensitivity reactions occurred in 14 patients (1.7%). The median number of chemoembolization procedures in these patients was 7 (range, 3–10). Mean dose of cisplatin per session was 22 mg (range, 9.2–35.7 mg), and the median total dose of cisplatin was 134 mg (range, 37–286 mg). On multivariate analysis, the only parameter that showed an independent association with hypersensitivity reactions was the performance of 3 or more than three chemoembolization procedures. Performance of more than three chemoembolization procedures with a cisplatin and Lipiodol suspension was found to be independently associated with hypersensitivity reactions. Patients undergoing repeated chemoembolization procedures with cisplatin and Lipiodol suspension may experience hypersensitivity reactions as an adverse effect." @default.
• W2020618126 created "2016-06-24" @default.
• W2020618126 creator A5013352947 @default.
• W2020618126 creator A5016882648 @default.
• W2020618126 creator A5018431544 @default.
• W2020618126 creator A5019763674 @default.
• W2020618126 creator A5023958825 @default.
• W2020618126 creator A5031469873 @default.
• W2020618126 creator A5034077858 @default.
• W2020618126 creator A5084808544 @default.
• W2020618126 creator A5090334402 @default.
• W2020618126 date "2010-08-01" @default.
• W2020618126 modified "2023-10-18" @default.
• W2020618126 title "Hypersensitivity Reactions to Transcatheter Chemoembolization with Cisplatin and Lipiodol Suspension for Unresectable Hepatocellular Carcinoma" @default.
• W2020618126 cites W1595116796 @default.
• W2020618126 cites W1603413676 @default.
• W2020618126 cites W1679583167 @default.
• W2020618126 cites W1910585037 @default.
• W2020618126 cites W1971046089 @default.
• W2020618126 cites W1971529620 @default.
• W2020618126 cites W1977650412 @default.
• W2020618126 cites W1983383221 @default.
• W2020618126 cites W1986249590 @default.
• W2020618126 cites W1990404563 @default.
• W2020618126 cites W1990464273 @default.
• W2020618126 cites W1991681679 @default.
• W2020618126 cites W2000574965 @default.
• W2020618126 cites W2010680051 @default.
• W2020618126 cites W2012636494 @default.
• W2020618126 cites W2022500941 @default.
• W2020618126 cites W2024779730 @default.
• W2020618126 cites W2031249029 @default.
• W2020618126 cites W2036846599 @default.
• W2020618126 cites W2043490217 @default.
• W2020618126 cites W2057671614 @default.
• W2020618126 cites W2077435026 @default.
• W2020618126 cites W2083752334 @default.
• W2020618126 cites W2086682824 @default.
• W2020618126 cites W2088312612 @default.
• W2020618126 cites W2088773971 @default.
• W2020618126 cites W2119615296 @default.
• W2020618126 cites W2122590547 @default.
• W2020618126 cites W2136029164 @default.
• W2020618126 cites W2151862971 @default.
• W2020618126 cites W2321119966 @default.
• W2020618126 cites W4238299055 @default.
• W2020618126 cites W4249574760 @default.
• W2020618126 doi "https://doi.org/10.1016/j.jvir.2010.04.014" @default.
• W2020618126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20619676" @default.
• W2020618126 hasPublicationYear "2010" @default.
• W2020618126 type Work @default.
• W2020618126 sameAs 2020618126 @default.
• W2020618126 citedByCount "14" @default.
• W2020618126 countsByYear W20206181262012 @default.
• W2020618126 countsByYear W20206181262013 @default.
• W2020618126 countsByYear W20206181262014 @default.
• W2020618126 countsByYear W20206181262016 @default.
• W2020618126 countsByYear W20206181262017 @default.
• W2020618126 countsByYear W20206181262020 @default.
• W2020618126 countsByYear W20206181262023 @default.
• W2020618126 crossrefType "journal-article" @default.
• W2020618126 hasAuthorship W2020618126A5013352947 @default.
• W2020618126 hasAuthorship W2020618126A5016882648 @default.
• W2020618126 hasAuthorship W2020618126A5018431544 @default.
• W2020618126 hasAuthorship W2020618126A5019763674 @default.
• W2020618126 hasAuthorship W2020618126A5023958825 @default.
• W2020618126 hasAuthorship W2020618126A5031469873 @default.
• W2020618126 hasAuthorship W2020618126A5034077858 @default.
• W2020618126 hasAuthorship W2020618126A5084808544 @default.
• W2020618126 hasAuthorship W2020618126A5090334402 @default.
• W2020618126 hasConcept C126322002 @default.
• W2020618126 hasConcept C126838900 @default.
• W2020618126 hasConcept C151956035 @default.
• W2020618126 hasConcept C167135981 @default.
• W2020618126 hasConcept C197934379 @default.
• W2020618126 hasConcept C2776694085 @default.
• W2020618126 hasConcept C2778019345 @default.
• W2020618126 hasConcept C2778239845 @default.
• W2020618126 hasConcept C2778448856 @default.
• W2020618126 hasConcept C71924100 @default.
• W2020618126 hasConcept C72563966 @default.
• W2020618126 hasConcept C90924648 @default.
• W2020618126 hasConceptScore W2020618126C126322002 @default.
• W2020618126 hasConceptScore W2020618126C126838900 @default.
• W2020618126 hasConceptScore W2020618126C151956035 @default.
• W2020618126 hasConceptScore W2020618126C167135981 @default.
• W2020618126 hasConceptScore W2020618126C197934379 @default.
• W2020618126 hasConceptScore W2020618126C2776694085 @default.
• W2020618126 hasConceptScore W2020618126C2778019345 @default.
• W2020618126 hasConceptScore W2020618126C2778239845 @default.
• W2020618126 hasConceptScore W2020618126C2778448856 @default.
• W2020618126 hasConceptScore W2020618126C71924100 @default.
• W2020618126 hasConceptScore W2020618126C72563966 @default.
• W2020618126 hasConceptScore W2020618126C90924648 @default.
• W2020618126 hasIssue "8" @default.
• W2020618126 hasLocation W20206181261 @default.
• W2020618126 hasLocation W20206181262 @default.
• W2020618126 hasOpenAccess W2020618126 @default.

• next